Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(0)
•••
Rsoleblocka
X
Comment by
Rsoleblocka
on Feb 08, 2022 8:50pm
RE:RE:I have a feeling
That is some long term prognasticating!
(5034)
•••
nozzpack
X
Comment by
nozzpack
on Feb 08, 2022 6:46pm
RE:I have a feeling
AGM ? That's next June..
(72)
•••
flashcash
X
Post by
flashcash
on Feb 02, 2022 2:21pm
I have a feeling
The AGM is not going to go well for the management unless something moves, news or value adding.
(72)
•••
flashcash
X
Comment by
flashcash
on Jan 12, 2022 10:20am
RE:156,200 Shares bought back in December
Steady as she goes, nice pension pot filler indeed !
(5034)
•••
nozzpack
X
Post by
nozzpack
on Jan 12, 2022 9:16am
156,200 Shares bought back in December
Pretty steady buybacks of about 160,000 shares per month. Couple more months and 1 million will have been bought back and cancelled . This is a serious buyback program ..
(5034)
•••
nozzpack
X
Post by
nozzpack
on Jan 11, 2022 5:21pm
Looking good
We have an excellent quarter coming our way and who know who is looking up our skirts..
(5034)
•••
nozzpack
X
Post by
nozzpack
on Dec 27, 2021 1:20pm
161,000 shares bought back in November
Eom
(106)
•••
Northforce13
X
Comment by
Northforce13
on Dec 18, 2021 8:14am
RE:Added Today
Me too... bid for another 30k at 1.55, got 15k filled Bought a bit last week at 1.69 and thought THAT was semi ridiculous
(271)
•••
microcaphobby
X
Post by
microcaphobby
on Dec 17, 2021 1:54pm
This is likely year end selling
It will see a january bounce. microcaps with under 100 mill market cap get sold off in this kind of market, unlelss there is instiitutional support-- of which this stock has none right now. Mull is a
...more
(194)
•••
Daudau11
X
Post by
Daudau11
on Dec 17, 2021 12:15pm
Added Today
Couldn't help myself and added... idk why but to me its too cheap to ignore.. trading like it has no future whatsoever or going bankrupt
(106)
•••
Northforce13
X
Comment by
Northforce13
on Dec 08, 2021 12:34pm
RE:RE:Forecast EPS for 2021
Yes, I sort of look at it that way too, from a purist perspective. Other perspective is the market values pharmas at 14x ebitda, with the d&a part of that equation therefore excluding the
...more
(5034)
•••
nozzpack
X
Comment by
nozzpack
on Dec 07, 2021 1:00pm
RE:RE:Forecast EPS for 2021
Investing is forward looking although hind casting forms part of the DD. One of those impairments was built into the share price and the other was optional but will remove a significant lability and
...more
(78)
•••
Stocker46
X
Comment by
Stocker46
on Dec 07, 2021 11:55am
RE:Forecast EPS for 2021
At the current SP, the price/earnings ratio is just over 8. It makes no sense to exclude impairment charges. Due to the nature of their business, there have been several impairment charges in past
...more
(5034)
•••
nozzpack
X
Post by
nozzpack
on Dec 06, 2021 9:25am
Forecast EPS for 2021
Removing one time impairment costs, $0.33 cad per share for the first 3 quarters on sales of $16.4 million US. As Q4 is the strongest quarter in the US, I see A4 net earnings in the $0.10-12 cad per
...more
(5034)
•••
nozzpack
X
Comment by
nozzpack
on Dec 02, 2021 6:46pm
RE:RE:RE:4 Quarter Trends in Absorica and Absorica +
Jeez, this is turning out to be a Mike Hammer dialogue. Go ahead . Make my day. Im starting to enjoy it. Cash is heavily discounted setting fallow in the treasury . Gross margins are very rich
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Eminent Continues to Hit Gold Mineralization at its Hot Springs Range Project in Nevada
Freegold Achieves over 90% Gold Recovery Using BIOX® and greater than 92% Gold Recovery using POX